Thymosin Alpha-1
Immune-modulating peptide that enhances immune system function
Clinical Research Score: 4/5 — Extensively studied in human clinical trials and approved in many countries for immune conditions, though not by the US FDA.
Categories: Immune Support, Anti-Aging / Longevity
What is Thymosin Alpha-1?
Thymosin Alpha-1 is the immune system's tune-up. People who seem to catch every cold, take forever to recover from illness, or just feel immunologically "run down" report a marked shift after starting it. Infections become less frequent. When illness does hit, recovery is faster and less severe.
The benefits are especially notable for people with chronic health challenges. Those dealing with persistent viral infections, autoimmune issues, or simply the immune decline that comes with aging describe feeling more robust, more resilient, and better defended against whatever is going around.
What makes Thymosin Alpha-1 particularly credible is that it's actually approved as a medication in over 35 countries for conditions like hepatitis B and C. It's one of the most well-studied immune peptides available, with decades of clinical data supporting its ability to restore and optimize immune function. The twice-weekly dosing makes it practical for long-term immune support.
How Thymosin Alpha-1 works
Thymosin Alpha-1 enhances the maturation and function of T-cells — the soldiers of your immune system. It helps immature immune cells develop into fully functional fighters, promotes the activity of dendritic cells (which identify threats), and increases your cells' ability to present antigens (flag invaders for destruction). It essentially trains and strengthens your immune army, making it more effective at identifying and eliminating threats.
Scientific overview
Thymosin Alpha-1 (Ta1) is a naturally occurring peptide originally isolated from the thymus gland. It is a potent immune modulator that enhances T-cell function, promotes dendritic cell maturation, and increases the expression of MHC class I molecules. It has been approved in several countries for the treatment of hepatitis B and C and is being studied for its potential in cancer immunotherapy.
Dosing
- Starting dose: 1.6 mg once per week
- Common dosage range: 1.6 mg twice per week
- Administration: Subcutaneous
- Half-life: ~2 hours
- Frequency: 2x per week